Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)

- May 7th, 2018

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved topical treatment for raised seborrheic keratoses (SKs) – benign skin growths that may be a cosmetic concern, especially when they appear on the face, neck or chest … Continued

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved topical treatment for raised seborrheic keratoses (SKs) – benign skin growths that may be a cosmetic concern, especially when they appear on the face, neck or chest area.

As quoted in the press release:

“With ESKATA, dermatologists may now offer their patients a topical treatment option for raised SKs,” said Brett Fair, Chief Commercial Officer of Aclaris.  “Our mission at Aclaris is to identify, develop and commercialize innovative therapies to address unmet needs in aesthetics and medical dermatology and immunology.  The introduction of ESKATA – six years in the making – delivers on this goal.”

ESKATA is a proprietary, high-concentration stabilized hydrogen peroxide topical solution designed for in-office application by a healthcare provider. It is a targeted treatment applied directly to the raised SK using a pen-like applicator. Typically, two treatments are required and scheduled approximately three weeks apart.

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply

Your email address will not be published. Required fields are marked *